10Y UST4.97%+0.20%30Y MTG6.76%+0.75%SOFR3.62%VNQ$94.10-0.24%XLRE$43.07-0.12%FED FUNDS3.63%
Real Estate Trail
Institutional Press Wire
PR Newswire · Capital

Saol Therapeutics Announces Strategic Investment of Up to $115 Million from Oaktree to Support Launch Preparation for SL1009

Via PR Newswire · September 15, 2026
Compiled by Real Estate Trail Editorial · September 15, 2026

Why this matters

Capital markets activity continues to be defined by the rotation from bank balance sheets to non-bank lenders. Private credit funds have raised record dry powder; banks have tightened CRE underwriting standards for the sixth consecutive quarter. The result is a market where well-sponsored deals clear, and marginal credit pays a meaningful spread to do so. For LPs, the allocation conversation has shifted decisively toward real estate debt, with equity allocations being deployed more selectively into operator-led platforms.

Editorial analysis · Real Estate Trail Editorial

On the RET wire

  • Disclosed capital deal value tracked in September 2026: $7.8B across 24 reported transactions.
  • 4 stories mentioning Oaktree on the wire in the past 90 days. Oaktree coverage

Computed from Real Estate Trail’s own tracked coverage

Excerpt from PR Newswire:
Financing will fund launch readiness for SL1009 and support lifecycle expansion into Congenital Lactic Acidosis and additional pain indications for SL1002 ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 15, 2026…
Read the full article at PR Newswire

External link. Real Estate Trail does not republish source content.

Related coverageCapital